ClinicalTrials.gov
ClinicalTrials.gov Menu

Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00319605
Recruitment Status : Completed
First Posted : April 27, 2006
Last Update Posted : May 25, 2012
Sponsor:
Information provided by (Responsible Party):
UCB Pharma

Brief Summary:
Phase IV, observational, post-authorization, cross sectional, open-label, multicenter study to evaluate the acceptability of oral solution of levetiracetam in patients with partial epilepsy as assessed by a questionnaire.

Condition or disease Intervention/treatment
Epilepsy Drug: Levetiracetam

Study Type : Observational
Estimated Enrollment : 600 participants
Time Perspective: Retrospective
Official Title: Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam (Keppra®) (SOLUCION Study)
Study Start Date : April 2006
Actual Primary Completion Date : July 2006
Actual Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Study populaton is defined. See Eligibility Criteria.
Criteria

Inclusion Criteria:

  • Patients 16 years old or older diagnosed with partial epilepsy with or without generalization receiving levetiracetam oral solution for at least 28 days before the study

Exclusion Criteria:

  • Patients with disturbances of the sense of taste and smell that can interfere with the assessment of the parameters of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00319605


  Show 54 Study Locations
Sponsors and Collaborators
UCB Pharma
Investigators
Study Director: Helena Marin Muñoz, MD UCB Pharma

Responsible Party: UCB Pharma
ClinicalTrials.gov Identifier: NCT00319605     History of Changes
Other Study ID Numbers: N01242
First Posted: April 27, 2006    Key Record Dates
Last Update Posted: May 25, 2012
Last Verified: May 2012

Keywords provided by UCB Pharma:
Cross sectional study
acceptability
levetiracetam
oral solution
Keppra

Additional relevant MeSH terms:
Pharmaceutical Solutions
Etiracetam
Piracetam
Anticonvulsants
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs